story of the week
Efficacy and Safety of Elacestrant in ER+/HER2− MBC With ESR1-Mutated Tumors Based on Prior Duration of Endocrine Therapy Plus CDK4/6i and in Clinical Subgroups
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Clinical Cancer Research
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Elacestrant in ER+, HER2- Metastatic Breast Cancer with ESR1-Mutated Tumors: Subgroup Analyses from the Phase III EMERALD Trial by Prior Duration of Endocrine Therapy plus CDK4/6 Inhibitor and in Clinical Subgroups
Clin. Cancer Res 2024 Oct 01;30(19)4299-4309, A Bardia, J Cortés, FC Bidard, P Neven, J Garcia-Sáenz, P Aftimos, J O'Shaughnessy, J Lu, G Tonini, S Scartoni, A Paoli, M Binaschi, T Wasserman, V KaklamaniFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.